Herrema Hilde, Derks Terry G J, van Dijk Theo H, Bloks Vincent W, Gerding Albert, Havinga Rick, Tietge Uwe J F, Müller Michael, Smit G Peter A, Kuipers Folkert, Reijngoud Dirk-Jan
Laboratory of Pediatrics, Center for Liver, Digestive, and Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Hepatology. 2008 Jun;47(6):1894-904. doi: 10.1002/hep.22284.
Medium-chain acyl-coenzyme A (CoA) dehydrogenase (MCAD) catalyzes crucial steps in mitochondrial fatty acid oxidation, a process that is of key relevance for maintenance of energy homeostasis, especially during high metabolic demand. To gain insight into the metabolic consequences of MCAD deficiency under these conditions, we compared hepatic carbohydrate metabolism in vivo in wild-type and MCAD(-/-) mice during fasting and during a lipopolysaccharide (LPS)-induced acute phase response (APR). MCAD(-/-) mice did not become more hypoglycemic on fasting or during the APR than wild-type mice did. Nevertheless, microarray analyses revealed increased hepatic peroxisome proliferator-activated receptor gamma coactivator-1alpha (Pgc-1alpha) and decreased peroxisome proliferator-activated receptor alpha (Ppar alpha) and pyruvate dehydrogenase kinase 4 (Pdk4) expression in MCAD(-/-) mice in both conditions, suggesting altered control of hepatic glucose metabolism. Quantitative flux measurements revealed that the de novo synthesis of glucose-6-phosphate (G6P) was not affected on fasting in MCAD(-/-) mice. During the APR, however, this flux was significantly decreased (-20%) in MCAD(-/-) mice compared with wild-type mice. Remarkably, newly formed G6P was preferentially directed toward glycogen in MCAD(-/-) mice under both conditions. Together with diminished de novo synthesis of G6P, this led to a decreased hepatic glucose output during the APR in MCAD(-/-) mice; de novo synthesis of G6P and hepatic glucose output were maintained in wild-type mice under both conditions. APR-associated hypoglycemia, which was observed in wild-type mice as well as MCAD(-/-) mice, was mainly due to enhanced peripheral glucose uptake.
Our data demonstrate that MCAD deficiency in mice leads to specific changes in hepatic carbohydrate management on exposure to metabolic stress. This deficiency, however, does not lead to reduced de novo synthesis of G6P during fasting alone, which may be due to the existence of compensatory mechanisms or limited rate control of MCAD in murine mitochondrial fatty acid oxidation.
中链酰基辅酶A(CoA)脱氢酶(MCAD)催化线粒体脂肪酸氧化中的关键步骤,该过程对于维持能量稳态至关重要,尤其是在高代谢需求期间。为了深入了解在这些条件下MCAD缺乏的代谢后果,我们比较了野生型和MCAD(-/-)小鼠在禁食期间以及脂多糖(LPS)诱导的急性期反应(APR)期间肝脏碳水化合物代谢的体内情况。与野生型小鼠相比,MCAD(-/-)小鼠在禁食或APR期间并未出现更严重的低血糖。然而,微阵列分析显示,在这两种情况下,MCAD(-/-)小鼠肝脏中过氧化物酶体增殖物激活受体γ共激活因子-1α(Pgc-1α)表达增加,而过氧化物酶体增殖物激活受体α(Pparα)和丙酮酸脱氢酶激酶4(Pdk4)表达降低,这表明肝脏葡萄糖代谢的控制发生了改变。定量通量测量显示,MCAD(-/-)小鼠在禁食时6-磷酸葡萄糖(G6P)的从头合成不受影响。然而,在APR期间,与野生型小鼠相比,MCAD(-/-)小鼠的这种通量显著降低(-20%)。值得注意的是,在这两种情况下,MCAD(-/-)小鼠中新形成的G6P都优先导向糖原。这与G6P从头合成减少一起,导致MCAD(-/-)小鼠在APR期间肝脏葡萄糖输出减少;在这两种情况下,野生型小鼠中G6P的从头合成和肝脏葡萄糖输出均得以维持。在野生型小鼠和MCAD(-/-)小鼠中均观察到的与APR相关的低血糖,主要是由于外周葡萄糖摄取增加所致。
我们的数据表明,小鼠中的MCAD缺乏会导致在暴露于代谢应激时肝脏碳水化合物管理发生特定变化。然而,这种缺乏单独在禁食期间不会导致G6P从头合成减少,这可能是由于存在补偿机制或小鼠线粒体脂肪酸氧化中MCAD的速率控制有限。